Related Experiment Video
Updated: May 17, 2026

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
[Treatment of pretibial myxoedema with pentoxifylline]
1Maros Megyei Klinikai Kórház, Bőrgyógyászati Klinika, Marosvásárhely.
Abstract:
Pretibial myxoedema is a rare symptom of Graves' disease. Histological studies detected mucopolysaccharide and glycosaminoglycan accumulation, and the role of anti-TSH receptor antibodies has been suggested. In this paper the authors present the case of a 34-year-old male patient with pretibial myxoedema treated successfully with pentoxifylline. In his case history multiple autoimmune diseases (type 1 diabetes mellitus, Graves' disease with severe ophthalmopathy) concomitantly occurred. His severe pretibial myxoedema was undiagnosed and untreated at the time of admission. Because of his diabetes, steroid was contraindicated, which made the choice of the treatment more difficult. He received first intradermal, then intravenous and, finally, oral pentoxifylline, which resulted in a regression of the dermatological symptoms. The beneficial effect of pentoxifylline might be explained by its inhibitory effect of proinflammatory cytokines and proliferation of fibroblasts, and the production of glycosaminoglycan. It was concluded that pentoxifylline can be an effective and safe treatment of pretibial myxoedema.
Insights
Pentoxifylline effectively treated severe pretibial myxoedema, a rare Graves' disease symptom. This treatment offers a safe alternative when steroids are contraindicated due to co-existing conditions like diabetes.
Area of Science:
- Endocrinology
- Dermatology
Background:
- Pretibial myxoedema is a rare manifestation of Graves' disease.
- Histological findings include mucopolysaccharide and glycosaminoglycan accumulation.
- Anti-TSH receptor antibodies are implicated in its pathogenesis.
Observation:
- A 34-year-old male with multiple autoimmune diseases (type 1 diabetes, Graves' disease with severe ophthalmopathy) presented with undiagnosed, untreated severe pretibial myxoedema.
- Steroid treatment was contraindicated due to his diabetes.
Findings:
- The patient received intradermal, intravenous, and oral pentoxifylline.
- Pentoxifylline treatment led to a significant regression of dermatological symptoms.
- Potential mechanisms include inhibition of proinflammatory cytokines, fibroblast proliferation, and glycosaminoglycan production.
Implications:
- Pentoxifylline represents a viable and safe therapeutic option for pretibial myxoedema.
- This approach is particularly valuable in patients with contraindications to standard therapies like corticosteroids.
- Further research into pentoxifylline's role in autoimmune dermatopathies is warranted.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...